Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NVTSSIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULNb4RSUUN3ME2wMlAxODR3ODDuUS=> NXTxOnRIW0GQR1XS
ES4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTK[lRIUUN3ME2wMlAxODZ3MzDuUS=> MU\TRW5ITVJ?
ACHN NFzZZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS1TWM2OD1yLkCwNFg5PyCwTR?= MVfTRW5ITVJ?
KYSE-510 NXT4c|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DEbWlEPTB;MD6wNFA6PzVibl2= NXjqN2lnW0GQR1XS
EW-7 NF7uXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfYb2NzUUN3ME2wMlAxOjV6IH7N NI\IdmJUSU6JRWK=
BFTC-905 NGfPVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPqdXRKSzVyPUCuNFA2OTVibl2= MUjTRW5ITVJ?
KE-37 NUHod2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEC1OlEhdk1? NHvXdWRUSU6JRWK=
SBC-5 NXeyTZhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDyWJdKSzVyPUCuNFA2PyCwTR?= M1;mV3NCVkeHUh?=
NKM-1 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfSWoZKSzVyPUCuNFA4ODlibl2= MVvTRW5ITVJ?
RH-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHSZg6UUN3ME2wMlAxPzF6IH7N MoG3V2FPT0WU
ALL-PO NXL5ToVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mdWZKSzVyPUCuNFA5OyCwTR?= MonXV2FPT0WU
QIMR-WIL MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M371O2lEPTB;MD6wNFg6PCCwTR?= NUDielJnW0GQR1XS
A375 NVL0e2ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILSdY5KSzVyPUCuNFA6QTVibl2= M2jpfnNCVkeHUh?=
SIG-M5 M3yzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjSdIlKSzVyPUCuNFExPCCwTR?= Ml3hV2FPT0WU
KGN M1fXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEGwPEBvVQ>? M4HrOnNCVkeHUh?=
EW-13 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zaUmlEPTB;MD6wNVEzKG6P MmHSV2FPT0WU
NCI-SNU-1 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;RNpRKSzVyPUCuNFE3KG6P NGPIfXZUSU6JRWK=
PSN1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvYTWM2OD1yLkCxOlUhdk1? MmHnV2FPT0WU
HUTU-80 M4n4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3iVIo{UUN3ME2wMlAyPjZibl2= NV\5bXRFW0GQR1XS
EW-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHxXYRKSzVyPUCuNFI{KG6P NYHyUZQ6W0GQR1XS
786-0 NH;wV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEKzJI5O NUjOd5Q5W0GQR1XS
ES1 NV7ZWFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG4TWM2OD1yLkCyOlghdk1? MVTTRW5ITVJ?
RKO NGS2NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEK3PUBvVQ>? NYfUR3NnW0GQR1XS
ESS-1 NVrFd4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEK4OkBvVQ>? MUjTRW5ITVJ?
SK-UT-1 NE[2d5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XOdWlEPTB;MD6wNlk4KG6P MXLTRW5ITVJ?
LB2241-RCC M1PlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvkeo9{UUN3ME2wMlA{OThibl2= MmjRV2FPT0WU
CHL-1 NVG3Nm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzPNodKSzVyPUCuNFMzPCCwTR?= NEfhZZJUSU6JRWK=
SW1783 NFrNTXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7sS5JKSzVyPUCuNFM{PiCwTR?= M3LNdHNCVkeHUh?=
MEL-JUSO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL3Z5VsUUN3ME2wMlA{QTFibl2= NX3zUoVOW0GQR1XS
HT-29 M1PLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HRVGlEPTB;MD6wOFE{KG6P NULNOIwxW0GQR1XS
SNG-M NWG4[4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC0fIk3UUN3ME2wMlA1OjVibl2= MVjTRW5ITVJ?
TE-15 NFezW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX1TWM2OD1yLkC0OlQhdk1? M3y5XXNCVkeHUh?=
HOS Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL4TWM2OD1yLkC0PEBvVQ>? MW\TRW5ITVJ?
BB65-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYftU|J6UUN3ME2wMlA2OTJibl2= NEfBW|NUSU6JRWK=
HCE-4 M4jZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnuTnZKSzVyPUCuNFUzQCCwTR?= NEjMT|lUSU6JRWK=
MHH-ES-1 NV\kU3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HXdmlEPTB;MD6wOVMyKG6P MVrTRW5ITVJ?
RPMI-7951 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD1yLkC1OFEhdk1? MkXKV2FPT0WU
IST-SL2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LLTmlEPTB;MD6wOVg1KG6P M1vkUHNCVkeHUh?=
CMK NVKzS21nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEW4OkBvVQ>? MX7TRW5ITVJ?
GR-ST MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS3TWM2OD1yLkC1PVUhdk1? M1ruXHNCVkeHUh?=
NALM-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwME[yNkBvVQ>? MUTTRW5ITVJ?
RPMI-6666 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rSNGlEPTB;MD6wOlUzKG6P MmXqV2FPT0WU
LC-2-ad Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;EVIJKSzVyPUCuNFY2OyCwTR?= NWDxTIhtW0GQR1XS
ARH-77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTaTWM2OD1yLkC3NVEhdk1? MYHTRW5ITVJ?
IST-MEL1 NV3ubVJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD2TWM2OD1yLkC3NlYhdk1? NHv5T2xUSU6JRWK=
SW1710 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTqRZM{UUN3ME2wMlA4PTFibl2= NXPINItQW0GQR1XS
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn6TGNYUUN3ME2wMlA5QDdibl2= M2PRbXNCVkeHUh?=
AGS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPkUlJpUUN3ME2wMlA6ODJibl2= MX;TRW5ITVJ?
NCI-H2122 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPseXM5UUN3ME2wMlA6PDZibl2= MUDTRW5ITVJ?
HSC-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm2V2VKSzVyPUCuNVAzKG6P NUDQZ4I1W0GQR1XS
AM-38 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLVeY1KSzVyPUCuNVIyKG6P MmnFV2FPT0WU
769-P MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLuTWM2OD1yLkGyN{BvVQ>? NX\CN4VrW0GQR1XS
RT-112 M4iwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3DWmlKSzVyPUCuNVI4KG6P MVnTRW5ITVJ?
MCF7 NI\Y[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm0e2pKSzVyPUCuNVM3KG6P M{jxT3NCVkeHUh?=
IGROV-1 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHRW|VKSzVyPUCuNVQ2KG6P M1XMdXNCVkeHUh?=
OCI-AML2 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnQOoMxUUN3ME2wMlE1PyCwTR?= MXjTRW5ITVJ?
NCI-H1299 M{nW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLa[|hKSzVyPUCuNVU4KG6P M3vNT3NCVkeHUh?=
A431 M2f2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUizJI5O MULTRW5ITVJ?
SW982 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMkGzJI5O M1;XT3NCVkeHUh?=
BB30-HNC NIrldZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZbWlEPTB;MD6yN|Ehdk1? MoG0V2FPT0WU
ACN MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDWOW1bUUN3ME2wMlI1PCCwTR?= NGWyO2pUSU6JRWK=
647-V NGq0OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLlTWM2OD1yLkK0PEBvVQ>? MVXTRW5ITVJ?
SK-PN-DW NFPJ[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK1TWM2OD1yLkK2OkBvVQ>? NF;jUVFUSU6JRWK=
LCLC-97TM1 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hy[WlEPTB;MD6yOlchdk1? NHLxc5ZUSU6JRWK=
LB1047-RCC NFy5dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH3ZnlKSzVyPUCuNlY6KG6P NWS5epNlW0GQR1XS
A2780 M3nVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XUfGlEPTB;MD6yO{BvVQ>? MmC5V2FPT0WU
C-33-A Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\DSmlEPTB;MD6yO|Mhdk1? Mm\IV2FPT0WU
NCI-H2228 M3XJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwM{G0JI5O M1vZPHNCVkeHUh?=
TE-5 NIj1N|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwM{G2JI5O NYS0fZh1W0GQR1XS
HC-1 NHHPNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{K3JI5O NVfsbJJCW0GQR1XS
SK-MES-1 NYfUUoF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PSNmlEPTB;MD6zNlghdk1? MYDTRW5ITVJ?
NCI-H1355 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTHc29KSzVyPUCuN|gyKG6P MmnHV2FPT0WU
YKG-1 M2rKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwNEG5JI5O NWLUXlVvW0GQR1XS
RS4-11 NXi0V21vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNEOzJI5O NWHHPFdyW0GQR1XS
Daoy NX[5bFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDxNpdKSzVyPUCuOFU3KG6P NX;KXlFTW0GQR1XS
A3-KAW NXjPVndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwNUWxJI5O MXrTRW5ITVJ?
SK-MEL-30 NEPmc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\VfIxKSzVyPUCuOVU1KG6P MX3TRW5ITVJ?
U031 NWXmdVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\tdWlEPTB;MD61OlUhdk1? MVfTRW5ITVJ?
SK-LMS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDtTWM2OD1yLkW3PEBvVQ>? MlnFV2FPT0WU
ES6 NXK1Oo9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfx[G9JUUN3ME2wMlU5PiCwTR?= M2fBeHNCVkeHUh?=
EoL-1-cell NFzJeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jxcmlEPTB;MD62NVYhdk1? M121TnNCVkeHUh?=
NCI-H2009 M2LQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jwWmlEPTB;MD62NVkhdk1? M3HpU3NCVkeHUh?=
A4-Fuk NXPxPYdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDEWXByUUN3ME2wMlYzPiCwTR?= MXvTRW5ITVJ?
KYSE-270 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnTdpZKSzVyPUCuOlM1KG6P NXTW[5dRW0GQR1XS
SK-LU-1 NED4RlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fIcGlEPTB;MD62OVUhdk1? MVPTRW5ITVJ?
SW872 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpVVRyUUN3ME2wMlc3PSCwTR?= NFm0dXdUSU6JRWK=
ES8 NWnuZWRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwN{igcm0> NVL4epZbW0GQR1XS
G-402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPCTWM2OD1yLke4OEBvVQ>? M{LISXNCVkeHUh?=
ATN-1 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi1TWM2OD1yLkiwO{BvVQ>? NFPpfGZUSU6JRWK=
DoTc2-4510 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW4XpNPUUN3ME2wMlkxOSCwTR?= NIXleXJUSU6JRWK=
MES-SA NEHJb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tUIZKSzVyPUCuPVA2KG6P NYTqPZB2W0GQR1XS
SF268 NYeyWI5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwOUK3JI5O NXfSZ2pSW0GQR1XS
SF539 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfWW5NKSzVyPUGuNFIhdk1? MnLVV2FPT0WU
NB69 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwMEWgcm0> Ml3kV2FPT0WU
8505C NFnYXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe5eJRKSzVyPUGuNFYhdk1? M3HYc3NCVkeHUh?=
CAL-12T NIHNZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;jTWM2OD1zLkC4JI5O NXnDbFFHW0GQR1XS
BHY NGqy[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;uSIZKSzVyPUGuNVQhdk1? NUm3O5h6W0GQR1XS
LB647-SCLC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwMUigcm0> MUDTRW5ITVJ?
CAL-62 M4jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FTWM2OD1zLkKyJI5O NVfIRYFuW0GQR1XS
MEG-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPvTWM2OD1zLkK3JI5O M4nxV3NCVkeHUh?=
MG-63 NEHLU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHITWM2OD1zLkOzJI5O MV;TRW5ITVJ?
SW620 NFLQb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHTTWM2OD1zLkO1JI5O MUjTRW5ITVJ?
A388 NUnY[mZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTHSplKSzVyPUGuN|Yhdk1? M2fWSXNCVkeHUh?=
BCPAP M2jpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MneyTWM2OD1zLkS1JI5O MoXlV2FPT0WU
P30-OHK NYHWWY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwNE[gcm0> Mn2zV2FPT0WU
Ca9-22 NFuxZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M365OGlEPTB;MT61OEBvVQ>? MnvHV2FPT0WU
VMRC-RCZ MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvZTWM2OD1zLkW0JI5O NWDKeIJLW0GQR1XS
LOXIMVI NXP1SW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNjDuUS=> MoHPV2FPT0WU
L-540 M1\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFwNjDuUS=> M{noO3NCVkeHUh?=
NTERA-S-cl-D1 NXH0c2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDvUGZKSzVyPUGuOlQhdk1? MUjTRW5ITVJ?
MFH-ino NXLMcW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX2[3hsUUN3ME2xMlY3KG6P MmfiV2FPT0WU
Calu-6 M{nWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLhWY01UUN3ME2xMlc{KG6P NIGxTIJUSU6JRWK=
HEL NH20UZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qxdmlEPTB;MT63PUBvVQ>? M{m2UXNCVkeHUh?=
CAL-33 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vJRmlEPTB;MT64PUBvVQ>? MYnTRW5ITVJ?
HSC-3 NX3JS4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzrTWM2OD1zLkmxJI5O MYfTRW5ITVJ?
KU812 M4jRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrmTWM2OD1zLkmxJI5O MXfTRW5ITVJ?
EB2 NIG4bpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwMEGgcm0> NFX6NnNUSU6JRWK=
SR NXTvepgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3NWd4UUN3ME2yMlEzKG6P MnXpV2FPT0WU
NCI-H2087 M4D0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWiz[lhPUUN3ME2yMlE1KG6P M4jIOnNCVkeHUh?=
H4 NG\QT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPnTWM2OD1{LkG4JI5O NUexc|RlW0GQR1XS
EW-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF24PYdKSzVyPUKuNlIhdk1? Mo\TV2FPT0WU
MC-IXC NWfQOINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\yO4hYUUN3ME2yMlI3KG6P NU\Uc5lMW0GQR1XS
NCI-H727 NYnINVZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTJwNUGgcm0> NFiwboxUSU6JRWK=
MRK-nu-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfVO45RUUN3ME2yMlU4KG6P MlzKV2FPT0WU
COLO-668 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmTWM2OD1{Lk[2JI5O MlvaV2FPT0WU
CGTH-W-1 NHHXUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S4bmlEPTB;Mj63NkBvVQ>? NUPqUZBNW0GQR1XS
CHP-212 NHzhSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;jbnRKSzVyPUKuO|Uhdk1? NXmzPYNzW0GQR1XS
GI-1 M4Oy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Tv[2lEPTB;Mj63OkBvVQ>? NWDqOG8zW0GQR1XS
HCC1806 NEfySohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnsO2hnUUN3ME2yMlkyKG6P NIDQOm9USU6JRWK=
HLE M3fzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PncWlEPTB;MzDuUS=> M{[3bXNCVkeHUh?=
HSC-2 NH;KV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5cZlKSzVyPUOuNFMhdk1? NYjwbVExW0GQR1XS
DMS-273 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7iPIVKSzVyPUOuNFchdk1? NUTRV4FQW0GQR1XS
DU-4475 NHW4cY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTNwMUSgcm0> MYfTRW5ITVJ?
LXF-289 M13sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf6[FFKSzVyPUOuN|Ehdk1? M3;ydHNCVkeHUh?=
PANC-03-27 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrK[pNKSzVyPUOuOVEhdk1? MWTTRW5ITVJ?
GAMG NWLsUXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNwN{Sgcm0> NG\CfpFUSU6JRWK=
NCI-H522 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPYVY9KSzVyPUSuN|Qhdk1? MXjTRW5ITVJ?
SW626 M3TURmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv4RpZoUUN3ME20MlQ3KG6P M{DYUnNCVkeHUh?=
HT-144 NWm2dm14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjMTWM2OD12LkmyJI5O Mn3NV2FPT0WU
MEL-HO MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwMU[gcm0> MY\TRW5ITVJ?
BE-13 NYjjdllGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETTbWlKSzVyPUWuNlEhdk1? MX3TRW5ITVJ?
VA-ES-BJ Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDwTWM2OD13LkK2JI5O MX7TRW5ITVJ?
NCI-H441 M3S4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofvTWM2OD13Lk[gcm0> MUjTRW5ITVJ?
KP-4 M4OxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwNkGgcm0> NHjEPGVUSU6JRWK=
LoVo NHTycYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGc5pKSzVyPUWuO|Ehdk1? NH23XpdUSU6JRWK=
HT-1080 NWO4VZRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjtS4hKSzVyPUWuPFMhdk1? NWntN2pLW0GQR1XS
GB-1 NVnMSWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\XcZFKSzVyPUWuPFQhdk1? NWD0TGpEW0GQR1XS
IA-LM NWXKPI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTuTWM2OD13LkmxJI5O NYn5RWNUW0GQR1XS
8-MG-BA NEDiSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[2N2lEPTB;NT65N{BvVQ>? MWfTRW5ITVJ?
SK-HEP-1 NYLWUXRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHL[HA3UUN3ME22MlE1KG6P MWTTRW5ITVJ?
697 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXJfnlKSzVyPU[uNlUhdk1? NV;BbWdjW0GQR1XS
KYSE-450 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPLVWJKSzVyPU[uN|Ihdk1? M4D1TXNCVkeHUh?=
HCC2998 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon0TWM2OD14LkO0JI5O MlTwV2FPT0WU
HD-MY-Z MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH60dWZKSzVyPU[uOlghdk1? MVrTRW5ITVJ?
OS-RC-2 M2LVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwNkigcm0> MXLTRW5ITVJ?
SF126 M2O5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fUUWlEPTB;Nz6wOUBvVQ>? NVrQcYpSW0GQR1XS
Ca-Ski Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TGd2lEPTB;Nz6wPUBvVQ>? MYTTRW5ITVJ?
NCI-H358 M2HSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KwOmlEPTB;Nz6xOkBvVQ>? M3vlcnNCVkeHUh?=
J82 NEjVPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTdwNEGgcm0> MoDUV2FPT0WU
NCI-H2342 NFrKXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[0cGlEPTB;Nz62N{BvVQ>? NXfDXmF6W0GQR1XS
OVCAR-8 M1PHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvHTWM2OD15Lkmgcm0> NGG1ZohUSU6JRWK=
TE-8 NHzHPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DkU2lEPTB;ODDuUS=> NUjnelg6W0GQR1XS
ETK-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfyVG5sUUN3ME24MlA5KG6P MXLTRW5ITVJ?
HAL-01 NE\TUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRThwMjDuUS=> MWTTRW5ITVJ?
KYSE-150 NYf1RnBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRThwNEegcm0> NH7XbGZUSU6JRWK=
NCI-H810 NUDadlNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPxUW4yUUN3ME24MlU3KG6P M3e1WXNCVkeHUh?=
ONS-76 M{TwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFznOFJKSzVyPUiuOlghdk1? Mni2V2FPT0WU
NMC-G1 NEKybplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0bpJ1UUN3ME24Mlc3KG6P NEXrTGRUSU6JRWK=
C3A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonHTWM2OD16Lki0JI5O MnT5V2FPT0WU
PA-1 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\lT3FKSzVyPUiuPVkhdk1? NFnRNpVUSU6JRWK=
SH-4 NEGwOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHjbos1UUN3ME25MlAzKG6P M4XkZ3NCVkeHUh?=
EFO-27 NIX4eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H5S2lEPTB;OT6wOUBvVQ>? NGnBV3BUSU6JRWK=
CAPAN-1 NGLN[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTSTWM2OD17LkKzJI5O NV\2Rpp{W0GQR1XS
DU-145 NFzxNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{iyU2lEPTB;OT6yPUBvVQ>? MlTKV2FPT0WU
A101D NIrWdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhemlEPTB;OT6zO{BvVQ>? NIfGcnZUSU6JRWK=
ST486 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nTdWlEPTB;OT60NUBvVQ>? NFzZbWxUSU6JRWK=
NCI-H1437 M3\jbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PaWGlEPTB;OT60NkBvVQ>? NXnW[VlPW0GQR1XS
HGC-27 M3\CdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm0TWM2OD17Lk[gcm0> M1XGWnNCVkeHUh?=
8305C M{m4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTlwNkSgcm0> MVPTRW5ITVJ?
OCUB-M NWLTbo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33wNGlEPTB;MUCuNFMhdk1? NEjFSVNUSU6JRWK=
COLO-679 NYXmTG1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFyLkC3JI5O M{Dje3NCVkeHUh?=
Detroit562 NY[2W2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjwTWM2OD1zMD60NkBvVQ>? MnjYV2FPT0WU
A204 NIPPcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LPWGlEPTB;MUGuNVYhdk1? NGrvUWpUSU6JRWK=
NCI-H1734 NHjwUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLRTWM2OD1zMT6yPUBvVQ>? NFnSb21USU6JRWK=
MC-CAR MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LONGlEPTB;MUGuOVghdk1? M4PVUHNCVkeHUh?=
NCI-H2170 NXvwe5dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37PVmlEPTB;MUGuPVchdk1? MWPTRW5ITVJ?
NCI-SNU-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7odmFYUUN3ME2xNk4yOyCwTR?= NWi3TotpW0GQR1XS
HCE-T NV3SZ4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rBUmlEPTB;MUKuOFIhdk1? Mmn0V2FPT0WU
KYSE-180 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7VTWM2OD1zMj64NUBvVQ>? NWjZU4N3W0GQR1XS
C8166 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTQTWM2OD1zMz6wPEBvVQ>? NVrlSZhPW0GQR1XS
NCI-H460 M4e1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF|LkW0JI5O M2rM[nNCVkeHUh?=
SNU-449 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF|Lke3JI5O MXrTRW5ITVJ?
MDA-MB-468 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3ZPI16UUN3ME2xOE4yOiCwTR?= NI[1boZUSU6JRWK=
COR-L23 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTjendKSzVyPUG0MlE{KG6P NX:xXpF[W0GQR1XS
CTV-1 M335emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPNTWM2OD1zND6xOEBvVQ>? NHLQVWtUSU6JRWK=
BL-41 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF2LkO3JI5O NF62VXlUSU6JRWK=
IGR-1 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0OlZKSzVyPUG0MlQzKG6P NWfvbHRKW0GQR1XS
TK10 M2DaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i4VmlEPTB;MUSuOFkhdk1? Mne0V2FPT0WU
REH MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF2LkWxJI5O NH[2coZUSU6JRWK=
LU-139 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF2LkW5JI5O NFrDUVJUSU6JRWK=
KP-N-YS M{i1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f5VGlEPTB;MUSuPVchdk1? MYDTRW5ITVJ?
PANC-10-05 NUL3XG04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nte2lEPTB;MUWuN|ghdk1? MnHUV2FPT0WU
HL-60 M1\zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfHTWM2OD1zNT62PUBvVQ>? NYe2Z3lKW0GQR1XS
T84 M4LCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTHWXJ{UUN3ME2xOU46PiCwTR?= MVPTRW5ITVJ?
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PxdWlEPTB;MU[uNFIhdk1? NYTSeG54W0GQR1XS
UM-UC-3 NFnBOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHHTWM2OD1zNj6xOkBvVQ>? MXzTRW5ITVJ?
TE-10 NILDUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nRdGlEPTB;MU[uNlEhdk1? M2\hOHNCVkeHUh?=
CAL-148 M3HB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\XO2lEPTB;MUeuNlMhdk1? MUfTRW5ITVJ?
BV-173 NHXOXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzqTWM2OD1zNz6yO{BvVQ>? M3fWPHNCVkeHUh?=
Calu-3 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP0TWM2OD1zNz6yPUBvVQ>? MYLTRW5ITVJ?
RPMI-2650 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3OdoZ{UUN3ME2xO{42QSCwTR?= NXqwSXhCW0GQR1XS
MKN45 NV\j[I42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLIRZZ5UUN3ME2xO{44OyCwTR?= MYTTRW5ITVJ?
NUGC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXLTWM2OD1zOD6zOEBvVQ>? NYH3V2dkW0GQR1XS
NCI-H520 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M363RWlEPTB;MUiuO|chdk1? M1PGNHNCVkeHUh?=
CCRF-CEM MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjhRoxKSzVyPUG4Mlg2KG6P MYnTRW5ITVJ?
NCI-H2405 NGPZXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HKTWlEPTB;MUmuNUBvVQ>? NVOzW2hlW0GQR1XS
ES7 NWLEdlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LHeGlEPTB;MUmuO|Yhdk1? NES3eFJUSU6JRWK=
BPH-1 NELyW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DUVGlEPTB;MkCuNlghdk1? NUHqc48xW0GQR1XS
SAS NVP5Z2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S5VmlEPTB;MkCuOUBvVQ>? M2fHcXNCVkeHUh?=
HuCCT1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe1Z5ZKSzVyPUKwMlU5KG6P Ml3CV2FPT0WU
LOUCY MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHhWG1EUUN3ME2yNE43PiCwTR?= NYnpcGhuW0GQR1XS
NCI-H292 NGrGeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJyLke5JI5O NYX3WoJsW0GQR1XS
G-361 M3y0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTVRZJKSzVyPUKxMlA4KG6P NEntZ3lUSU6JRWK=
M059J NGXhSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\YUWlEPTB;MkGuNFghdk1? NUHMT5RzW0GQR1XS
NCI-H1651 NHyzN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nsU2lEPTB;MkGuNVEhdk1? NET0[VFUSU6JRWK=
KALS-1 NF;kbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LIfGlEPTB;MkGuN|khdk1? M3O2U3NCVkeHUh?=
DJM-1 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJzLkW5JI5O MlXhV2FPT0WU
AU565 NV\5TWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fHVmlEPTB;MkGuPFMhdk1? MXTTRW5ITVJ?
HCC38 M163fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrkOppLUUN3ME2yNU46PSCwTR?= NFzz[WhUSU6JRWK=
U251 NW\IV5R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;BUlVKSzVyPUKyMlI4KG6P M2\nN3NCVkeHUh?=
ABC-1 M4rkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PmVWlEPTB;MkKuOlUhdk1? NXrFfIhGW0GQR1XS
SK-NEP-1 NWPRfldRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTjTWM2OD1{Mj65N{BvVQ>? NUHGSHlRW0GQR1XS
CESS NV7VN3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\NUphKSzVyPUKzMlE6KG6P MWnTRW5ITVJ?
MIA-PaCa-2 M1vW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ|LkO2JI5O NX7yUVM2W0GQR1XS
SUP-T1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ|LkS3JI5O Mn\WV2FPT0WU
L-428 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljsTWM2OD1{Mz62NkBvVQ>? M2HyZ3NCVkeHUh?=
SW954 NVrQUmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC1bohKSzVyPUKzMlY5KG6P MoDxV2FPT0WU
HO-1-N-1 NVr1Sml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDjT2RKSzVyPUKzMlc4KG6P NXvHOJNIW0GQR1XS
CHP-126 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL3XmdKSzVyPUK0MlE1KG6P NYTGWpliW0GQR1XS
HMV-II M1nPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLHSlNKSzVyPUK0MlM1KG6P Ml;VV2FPT0WU
NB10 NIPDWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYXWEyUUN3ME2yOE4{PyCwTR?= M{fVbXNCVkeHUh?=
A172 M4\lbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G1UGlEPTB;MkSuO|Ehdk1? Mnz4V2FPT0WU
MONO-MAC-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfhTWM2OD1{ND64OEBvVQ>? NWC2OFV6W0GQR1XS
NCI-H1650 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXtSW57UUN3ME2yOU41KG6P MUDTRW5ITVJ?
NH-12 NWjobFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17GeGlEPTB;MkWuOUBvVQ>? M2G5dHNCVkeHUh?=
ML-2 M1nYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;6TWM2OD1{NT63OEBvVQ>? NITvenFUSU6JRWK=
MZ2-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrxb5NrUUN3ME2yOk4zOiCwTR?= NXfpU5ZpW0GQR1XS
COLO-684 NXTyNHlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3hZpFKSzVyPUK2MlQyKG6P MVnTRW5ITVJ?
HuP-T4 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T1NWlEPTB;MkeuN{BvVQ>? M3fUNnNCVkeHUh?=
SW837 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ5Lk[yJI5O NH;URmxUSU6JRWK=
MDA-MB-231 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ5Lke4JI5O MXfTRW5ITVJ?
KYSE-140 NVrKSI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDZTWM2OD1{Nz65NUBvVQ>? Mn7PV2FPT0WU
NOMO-1 NV3BNo5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK0RVRKSzVyPUK4MlY5KG6P NVj4cIpiW0GQR1XS
GP5d NFqzV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ6LkeyJI5O M3Wx[XNCVkeHUh?=
COR-L105 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jwbmlEPTB;MkmuOFIhdk1? NH;lNmJUSU6JRWK=
LS-411N NGfxXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1{OT64PEBvVQ>? M37XXHNCVkeHUh?=
NY MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXSyU2RoUUN3ME2zNE4yQCCwTR?= MYPTRW5ITVJ?
NCI-H2030 M2X3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELVRldKSzVyPUOwMlQ2KG6P MUjTRW5ITVJ?
CCF-STTG1 M17ITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG3PGVKSzVyPUOxMlQzKG6P MkXMV2FPT0WU
NCI-H1703 NUTJZpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PYXGlEPTB;M{GuO|ghdk1? NITSUGFUSU6JRWK=
TUR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;P[3FKSzVyPUOyMlA{KG6P M2[ye3NCVkeHUh?=
NOS-1 M3TzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorkTWM2OD1|Mj60OEBvVQ>? M3;WU3NCVkeHUh?=
A2058 NE\jZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG1TWM2OD1|Mj64N{BvVQ>? MUXTRW5ITVJ?
LCLC-103H NEGzbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTN|LkK1JI5O MnL0V2FPT0WU
NCI-H510A MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN|LkK3JI5O MlHvV2FPT0WU
BC-1 NV\mdINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN|Lke3JI5O NG[xUJhUSU6JRWK=
SK-CO-1 M{DjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[xeXRKSzVyPUO0MlAyKG6P M4Xo[HNCVkeHUh?=
A673 NHTZ[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPfYJKSzVyPUO0MlE4KG6P NV\ETlFJW0GQR1XS
VM-CUB-1 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfJNWdQUUN3ME2zOE43QSCwTR?= M1\MXXNCVkeHUh?=
HH MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvuZ2FqUUN3ME2zOU4xPiCwTR?= MWLTRW5ITVJ?
CAL-27 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG5WVRYUUN3ME2zOU4yPiCwTR?= NWS3WIl[W0GQR1XS
NEC8 NGHlOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\0N4pKSzVyPUO1MlM4KG6P Mlm0V2FPT0WU
BxPC-3 NVq1SYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DSdGlEPTB;M{[uPVEhdk1? NFnI[XhUSU6JRWK=
SNB75 NFrkVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDYc3pKUUN3ME2zO{4zPCCwTR?= MlvxV2FPT0WU
NB13 NH7pSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPvTWM2OD1|OD6yN{BvVQ>? NHTQU5lUSU6JRWK=
SK-OV-3 M{LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInwW4pKSzVyPUO4Mlc1KG6P MUXTRW5ITVJ?
ME-180 NXnmVYtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHyTWM2OD1|OD64JI5O NYjhUZY{W0GQR1XS
JiyoyeP-2003 NID3[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPte2tKSzVyPUO5MlM5KG6P MXLTRW5ITVJ?
LU-134-A Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTITWM2OD12MD6wNkBvVQ>? NIHq[ppUSU6JRWK=
LS-123 M4DE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXoUlNKSzVyPUSwMlI5KG6P MYHTRW5ITVJ?
COLO-800 NY\yT4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTRyLkW2JI5O NIWwSoRUSU6JRWK=
LB831-BLC M376Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYS5NKSzVyPUSxMlg2KG6P M335NHNCVkeHUh?=
NCI-H747 M1q0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3PTWM2OD12Mj6yPEBvVQ>? MkPyV2FPT0WU
MZ7-mel NH2zSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyyRZpKSzVyPUSyMlY3KG6P MkDYV2FPT0WU
GT3TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf1TWN5UUN3ME20Nk44OiCwTR?= MV7TRW5ITVJ?
MOLT-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuTWM2OD12Mz6wOUBvVQ>? MkfiV2FPT0WU
23132-87 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLiTWM2OD12Mz6wOUBvVQ>? NEfKXHhUSU6JRWK=
PF-382 NVq2N2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD12ND6yNkBvVQ>? NISxcHFUSU6JRWK=
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfRUZhiUUN3ME20OE43KG6P NWPoOGdlW0GQR1XS
SW756 NEnnfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES5Z|JKSzVyPUS1MlE1KG6P NUfk[W9tW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03579836 Recruiting Locally Advanced Pancreatic Cancer|Metastatic Pancreatic Cancer BeyondBio Inc. May 9 2018 Phase 1|Phase 2
NCT03449901 Recruiting Soft Tissue Sarcoma Washington University School of Medicine|Polaris Pharmaceuticals Inc. May 9 2018 Phase 2
NCT03422523 Recruiting Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma University Hospital Southampton NHS Foundation Trust|Hoffmann-La Roche May 9 2018 Phase 2
NCT02181634 Completed Cholangiocarcinoma PrECOG LLC.|Celgene Corporation December 9 2014 Phase 2
NCT01924260 Active not recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|National Cancer Institute (NCI)|Takeda August 9 2013 Phase 1
NCT01535924 Active not recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Beth Christian|Ohio State University Comprehensive Cancer Center February 9 2012 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID